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a b s t r a c t 
Background: Blood pressure-lowering medications, antiplatelet drugs and statins are often prescribed to asymptomatic patients with white matter hyperintensities 
(WMH). A clinical trial is needed, but potential trial participants would be excluded if they already had another indication to take the medication. It is likely that 
many patients with WMH would already have a recognised vascular-related indication for these drugs. 
We used data from the UK Biobank study to determine what proportion of people with WMH were not taking these drugs and would be potentially able to enter a 
clinical trial of antiplatelet drugs, statins, or BP-lowering medication. 
Methods: We used the UK Biobank MRI sub-study of healthy volunteers aged 40–70 years as our cohort. We considered that WMH volumes in the top quartile 
(2.7–89 mls) were severe enough for a patient to be at risk of progression and be offered treatment. Such patients could also be included in a hypothetical clinical 
trial if there were no contraindications. Using the product licenses, we defined exclusion criteria for four hypothetical clinical trials of aspirin, clopidogrel, statins, 
and tight BP control. We then calculated what proportion of patients would still be eligible if these criteria were applied. 
Results: 5794/23,179 patients had WMH in the top quartile. Of these, 4006/5794 69% (95% CI 68–70%) would be eligible for a trial of aspirin; with 81% (95% CI 
80–82%) eligible for a trial of clopidogrel; 56% (95% CI 55–58%) of patients would be eligible to enter into a trial of a lower BP target, and 58% (95%CI 57–59%) 
would be able to enter a trial of a statin. 
Conclusions: Over 80% of patients with WMH in the UK biobank would be eligible to enter a trial of an antiplatelet and just over half would be eligible to enter a 


































White matter hyperintensities on MRI (WMH) are a widely recog-
ised imaging feature of cerebral small vessel disease (SVD). SVD is as-
ociated with increased risk of stroke, dementia, disability, and death
 1 , 2 ]. Whilst there is no proven evidence based treatment, many clini-
ians treat small vessel disease (including WMH) by targeting vascular
isk factors with blood pressure (BP) lowering medications, antiplatelet
gents and statins [3] . 
To date both established [4] and proposed [5] trials of potential
reatments for SVD have focused on the patient with a lacunar stroke: a
ymptomatic lacunar stroke is a time when a patient can be identified
s having currently active SVD. However, it may be beneficial to start
reatment of SVD in its earlier, largely asymptomatic, stages. ∗ Corresponding author at: The Centre for Health Science, Centre for Rural Health,
E-mail address: Stephen.makin@abdn.ac.uk (S. Makin). 
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 http://creativecommons.org/licenses/by-nc-nd/4.0/ ) Logically, antihypertensives, antiplatelets and statins may be ben-
ficial. Intensive blood pressure control may reduce the size of WMH
 6 , 7 ] as uncontrolled hypertension in midlife increases the risk of de-
entia in later life [8] . Antihypertensive treatment, antiplatelet drugs
nd statins are gold standard treatment in people presenting with an
schaemic stroke (including lacunar stroke), therefore it is reasonable
o assume that people with WMH, without a symptomatic stroke, would
enefit from treatment. However, the secondary prevention of small sub-
ortical strokes (SPS3) trial found dual antiplatelet agents to increase
ortality and haemorrhage risk in patients with lacunar stroke [9] . 
Given that antiplatelets, antihypertensives, and statins are already
rescribed by some practitioners; given the clinical uncertainty about
he benefit of using these drugs for incidental asymptomatic SVD, a
arge-scale trial is needed to determine if these are justifiable therapies.
owever, recruitment to such a trial may be difficult as many potential Old Perth Road, Inverness IV2 3JH, University of Aberdeen, UK. 
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articipants may either be taking the medication for another indication
r have a known contra-indication. 
Due to the above, we aimed to establish what proportion of asymp-
omatic study participants with WMH on imaging would be able to en-
er a hypothetical clinical trial. We used the neuroimaging, and self-
eported clinical and medication data from the UK Biobank. This is a
arge prospective observational study of healthy volunteers whose aim
s to improve the prevention, diagnosis and treatment of a wide range
f illnesses [10] . 
. Methods 
All participants provided written consent to be included in the UK
iobank and had a full understanding of the resource’s aims and pur-
ose. We operated and used the data under the framework of the
K Biobank’s ethics and governance council ( https://www.ukbiobank.
c.uk/wpcontent/uploads/2011/05/EGF20082.pdf) , this analysis was
ompleted under application number 17,689. This study was covered
y the generic ethical approval for UK Biobank studies from the NHS
ational Research Ethics Service (approval letter dated 17th June 2011,
ef 11/NW/0382). 
.1. Participants 
Adult volunteers were recruited between 2006 and 2010 and were
ssessed with a standard protocol. At baseline recruitment into the UK
iobank, health and lifestyle data were collected for each participant
hrough a questionnaire, physical measurements, and biological sam-
les [11] . Baseline assessment included comprehensive medication data,
oth prescribed and over the counter. A subset of participants had sub-
equent neuroimaging with MRI, beginning in 2014. 
.2. Small vessel disease assessment 
The UK biobank imaging protocol compromises MRI sequences in-
luding T1, T2 FLAIR, diffusion and susceptibility-weighted imaging
 10 , 12 ]. For our assessment of SVD; we used T1 and T2 FLAIR images,
ocusing on WMH and assessing lesion volume as a continuous variable
2] . The methodology for acquiring the MRI data, including the method
or calculating WMH volumes, has been described previously [ 10 , 13 ].
riefly, all images were acquired using a Siemens 32-channel head coil
 14 , 15 ]. T2 FLAIR images were also acquired in the sagittal orientation
ut with a resolution of 1.05 × 1 × 1 mm [10] . The image processing
as carried out using an automated sequence, which extracted volume
f different tissues including WMH from the T1 and T2 FLAIR sequences.
We defined SVD status according to WMH volume quartiles, with
hose in the top quartile of WMH volumes defined as having SVD eligible
or treatment in a trial. In the absence of a recognised threshold above
hich WMH is considered pathological, we considered that this was a
opulation of people who had some WMH and were well enough to take
art in a research study, and thus were analogous to the population who
ould be considered for a clinical trial. 
.3. Defining eligibility criteria for clinical trials 
We then defined and applied a series of trial inclusion/exclusion cri-
eria to this SVD cohort and assessed the proportion eligible for study
nclusion. We chose four possible strategies that may have benefit in
VD: BP lowering, statins, aspirin and clopidogrel. In designing each
rial protocol, we consulted the Electronic Medicine Compendium and
ritish National Formulary (BNF) version 77 to determine cautions, in-
ications and contraindications [ 16 , 17 ]. Additionally, for the trial of BP
owering we used a modified version of the inclusion and exclusion cri-
eria of the 2015 SPRINT trial, which was a trial of BP lowering to a
arget rather than using particular medications [18] ( Fig. 1 ). 2 Broadly, we assumed that patients would not be able to participate in
he clinical trial if they had either an existing indication for treatment,
r an existing contraindication or caution for treatment. Therefore pa-
ients with previous symptomatic stroke or TIA would not be recruited
o a trial, as that is a well-recognised indication for treatment with an-
ihypertensives, antiplatelets or statins. We also assumed that a patient
ith a relative contraindication would be unlikely to be recruited into a
linical trial. The exclusion criteria for trials of BP lowering and statins
re shown in Table 1 and for antiplatelets are shown in Table 2 . 
We used simple descriptive statistics for baseline characteristics of
hose defined as having SVD eligible, for treatment in a trial, and for
hose who could be included in each of our theoretical trials. We also
ssessed baseline differences in demographics and vascular risk factors
etween those defined as having SVD eligible for treatment in a trial, and
ompared these with the rest of the UK Biobank cohort using parametric
nd proportion tests as required. All statistical analysis was carried out
n Minitab version 9. If data was missing from physiological measure-
ents carried out at study visits, the patient was excluded from analysis
equiring that measurement. If data on whether a patient had a condi-
ion was missing, the patient was assumed not to have the condition. 
As relatively few biobank participants had severe WMH, we carried
ut a subgroup analysis in which the analysis was repeated for the sub-
roup of participants with a WMH volume of 20 mls or greater. 
. Results 
At the time of data extraction (19/05/2018), brain imaging data
ere available for 23,179 participants of the 502,628 recruited to UK
iobank. 5794 of the 23,179 had a total WMH volume in the highest
uartile with a range of 2.7–89mls, and median 5.2mls. The second-
ighest quartile had a median of 1.6mls WMH volume; both the third
nd fourth quartiles had a median of 0mls of WMH volume. Data on
lood pressure was missing from 57 participants. The participants with
igh WMH ( Table 3 ) had a mean age of 69 years, 52% were male, 44%
ere either current or previous smokers, 37% had pre-existing vascu-
ar disease, and 9% had pre-existing cardiac disease. The mean BP was
41/80, and the majority - 67% (3966/5794) - were on at least one
P-lowering drug. 
The participants with high WMH who could be entered into a clinical
rial were less likely to have a pre-existing vascular or cardiac condition
nd were slightly younger, than those that could not be entered into the
linical trial. 
.1. Aspirin and Clopidogrel 
4006/5794 (69.1%, 95% CI: 68.0–70.3%) were eligible for a trial of
spirin compared to 4710/5794 (81.3%, 95% CI: 80.3–82.3%) being eli-
ible for a trial of clopidogrel. Reasons for exclusion are shown in Fig. 2:
92 patients (13%) would have been excluded as they were already on
n antiplatelet or anticoagulant drug. More patients were eligible for a
rial of clopidogrel, as 593 patients were excluded from the aspirin trial
ue to a diagnosis of asthma, which is a relative contraindication. 
.2. Antihypertensives 
3262/5794 (56.3%, 95% CI: 55.0–57.6%) could be recruited to a
tudy of BP lowering to a target of 120 mmHg using similar eligibility
riteria to the SPRINT trial. 1606 were excluded as they had a systolic
P below 130, and 1802 did not have hypertension which would have
ade them eligible to be included in SPRINT [19] , (i.e. 130–180 mmHg
n ≤ 1 medication, 130–170 mmHg on ≤ 2 medications, 130–160 mmHg
n ≤ 3 medications, 130–150 mmHg on ≤ 4 medications). SPRINT used
tratified recruitment to maximize the cohort more likely to benefit from
reatment. 
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Table 1 
Exclusion Criteria for trial of BP- lowering or statin. 
BP Lowering exclusion criteria Statin exclusion criteria 
Indication for a specific BP medication ∗ 
Secondary Hypertension 
Diabetes 
History of Stroke 
History of Polycystic Kidney Disease 
Glomerulonephritis 
History of dementia 
Organ transplant 
Systolic BP < 130 mmHg 
Did not have prospect for medications to be increased as per sprint 
protocol e.g. to be included patients needed: 
130–180 mmHg on ≤ 1 medication 
130–170 mmHg on ≤ 2 medication 
130–160 mmHg on ≤ 3 medication 
130–150 mmHg on ≤ 4 medication 
Currently on any of the following medications:Any lipid lowering 
therapy including statins, fibrates, and othersCiclosporinDiagnosis of 
one of the following:High cholesterolAny arrhythmiaLiver DiseaseAny 
hepatitis, liver failure, cirrhosis, chronic liver disease, any other 
liver/biliary/pancreas problemHypothyroidismAny pancreatic disease 
(including pancreatitis)Any biliary tree diseaseBowel obstruction or 
malabsorption (including coeliac disease)Any haemorrhagic disorder 
○ Platelet disorder;Essential thrombocytosis; Genetic 
haematological disorder; Aplastic anaemia; DVT; Cerebral 
haemorrhage; Menorrhagia; Polycythaemia Vera; Excessive 
bleeding; Myeloproliferative disorder; Anaemia; Neutropenia; 
Sub-Arachnoid haemorrhage; Subdural haemorrhage 
Peptic ulcerAny neurodegenerative diseaseAt increased risk of 
muscular toxicity:Diagnosis of myopathy; rhabdomyolysis; renal 
failure; or any other renal disease. 
∗ Specific BP indicationsAlpha blockers: benign prostatic hyperplasia, vasospasm, ACE inhibitors: heart Failure, diabetic nephropathy, my- 
ocardial infarction, angiotensin II receptor blockers: heart failure, diabetic nephropathy, beta blockers: heart failure, myocardial infarction, 
angina, arrhythmias, supraventricular tachycardia, atrial fibrillation, thyrotoxicosis, anxiety/panic attacks, migraine prophylaxis, glaucoma, es- 
sential tremor, calcium channel blockers: angina, supraventricular tachycardia, raynaud’s, migraines. Diuretics: heart failure, pulmonary oedema, 
nephrogenic diabetes insipidus, primary hyperaldosteronism, ascites/oedema in hepatic cirrhosis, malignant ascites, nephrotic syndrome. Ni- 
trovasodilators: angina, left ventricular failure. 
Table 2 
Exclusion criteria for antiplatelet trials. 
Aspirin exclusion criteria Clopidogrel exclusion criteria 




Atrial Fibrillation (which would be an indication for anticoagulation) 
Peripheral arterial disease 
After bypass-surgery 
On any antiplatelet therapy or anticoagulation 
Caution for Aspirin: 




History of peptic ulcers 
Renal failure 
History of coagulation and haematological disorders ∗ 




Pre-existing indication for clopidogrel: 




Atrial Fibrillation(which is likely to be an indication for 
anticoagulation) 
On any antiplatelet therapy or anticoagulation 
Caution for Clopidogrel: 
History of coagulation and haematological disorders ∗ 
History of peptic ulcer 
Renal failure 
Hepatic Failure 
History of bleeding events † 
∗ Coagulation and haematological disorders defined as one or more of: essential thrombocytosis, deep vein thrombosis, genetic haematological 
disorder, platelet disorder, aplastic anaemia, haemophilia, polycythaemia vera, myeloproliferative disorders, anaemia, neutropenia † Bleeding 
events defined as one or more of: cerebral haemorrhage, menorrhagia, excessive bleeding, subarachnoid haemorrhage, subdural haemorrhage. 
Table 3 
Comparison of baseline characteristics of eligible participants, by trial, to all patients with SVD. 
Trial Full SVD cohort BP lowering Lipid lowering Aspirin Clopidogrel 
Total eligible 5794 3262 3368 4006 4710 
Mean age (years) 68.65 68.85 p = 0.142 67.6 p < 0.001 ∗ 68.29 p = 0.006 ∗ 68.22 p = 0.001 ∗ 
Males 3034 (52.4%) 1823 (55.9%) p = 0.001 ∗ 1657 (49.2%) p < 0.001 ∗ 1943 (48.5%) p < 0.001 ∗ 2319 (49.2%) p = 0.001 ∗ 
Mean SBP/DBP (mmHg) 140.6/79.4 147.0/82.3 p < 0.001 ∗ 140.3/79.7 p = 0.09/0.08 140.6/79.5 p = 0.899/0.574 140.7/79.6 p = 0.886/0.230 
Positive smoking history 2524 (43.6%) 1370 (42.0%) p = 0.145 1369 (40.6%) p = < 0.001 ∗ 1632 (40.7%) p = 0.005 ∗ 1958 (41.6%) p = 0.001 ∗ 
≥ 1 vascular condition 2150 (37.1%) 1159 (35.5%) p = 0.134 838 (24.8%) p < 0.00.1 ∗ 1169 (29.2%) p < 0.001 ∗ 1416 (30.1%) p < 0.001 ∗ 
≥ 1 heart condition 517 (8.9%) 118 (3.6%) p < 0.001 ∗ 49 (1.4%) p < 0.001 ∗ 60 (1.5%) p < 0.001 ∗ 70 (1.5%) p < 0.001 ∗ 
Means for age, SBP, and DBP compared using two-sample t -tests. Proportions of males, current/former smokers (Positive smoking history), participants with one 
or more vascular conditions, and one or more cardiac conditions compared using two-sample z -tests. P -values are given, and statistically significant differences 
to the full SVD cohort represented by ( ∗ ). 
3 
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Fig. 1. Patients eligible for trials of (A) BP lowering and (B) statin medication. Participants may have been ineligible for multiple reasons. 
























3171/5794 (58%, 95% CI: 57–59%) of participants were eligible for
reatment in a trial of a statin. 1765 would have been excluded because
hey were already taking a statin, and the remainder of the excluded
roup either had a contraindication or an existing indication. 
As it was possible that the population of patients with SVD eligi-
le for a trial is skewed so that it is not representative of those with
ore severe SVD, we analysed a subgroup of participants with WMH
ver 20 mls. Of the 332/5794 patients who had WMH volume over
0 mls, 57% (190/332) could have joined a trial of BP lowering similar
o SPRINT, 45% (148/332) could join a trial of a statin, 63% (210/332)
ould join a trial of aspirin, and 72% (240/332) could join a trial of4 lopidogrel. This was not significantly different to participants with SVD
ligible for a trial. 
. Discussion 
This project identified that a majority of UK Biobank participants,
ith MRI data and radiological SVD, could be theoretically recruited to
rials that repurpose cardiovascular medication. The majority were nei-
her already on the medication for another reason, nor had a contraindi-
ation to taking it. Therefore, 69% could be potentially be recruited to
 trial of aspirin, 81% to a trial of clopidogrel, 58% to a trial of a statin,
nd 56% to a trial of BP-lowering medication. 















































































































The strengths of this work include a relatively large sample size, par-
icularly for an imaging study, with access to the full medical history and
etails of medications. Whilst these participants may not be representa-
ive of the general population, it is likely they are more representative
f patients who would be willing to take part in clinical research. 
Drawbacks include that this data was largely relating to a group of
ealthy volunteers with early WMH (median 5.2 mls). It is recognised
hat the UK biobank participants are healthier than average for their
ge; [20] however, the associations between known risk factors and
isease are similar to more representative cohorts indicating general-
sable results [21] . The cohort’s median WMH value was lower than
hat of studies using symptomatic patients such as the Leukoarosis and
isability (LADIS) study of symptomatic SVD (20 ml), and older healthy
olunteers [22] such as the Lothian birth cohort of healthy 73 year-
lds (7.9 ml) [23] . However, it is similar to the WMH volume in the
PRINT – MIND study (3.2 ml), which recruited patients over 50 with
ascular risk factors. Whilst, WMH volume is not exactly equivalent to
emi-quantitative visual rating scales such as Fazekas Score [24] , our
edian WMH volume was roughly equivalent to a Fazekas score of 1
25] . Although there are a number of causes of WMH other than SVD
uch as infection and multiple sclerosis, the vast majority of WMH seen
n the UK Biobank are due to vascular causes. Participants with acute
erebral infections are unlikely to be well enough to volunteer for an
maging study, only 0.3% of participants had a diagnosis of multiple
clerosis [26] , and WMH in UK Biobank were strongly associated with
ascular risk factors [27] . 
It is possible that as this population is skewed so that it is not repre-
entative of those with more severe SVD; however, the subgroup analysis
f participants with WMH of 20 mls or more, did not produce signifi-
antly different findings. 
It is likely that these figures are an overestimation of the proportion
f patients who would enter a clinical trial: there will also be other con-
raindications or cautions not apparent from the UK Biobank data. For
he most part, recruitment into clinical trials is less than estimated, with
nly 56% of clinical trials funded by the UK Health Technology Assess-
ent program reaching their recruitment target, the majority with an
xtension [28] . The SPRINT trial randomised 60% of screened patients.
n practice, between 5 and 20% of the eligible population are recruited
nto clinical trials for a variety of reasons. Indeed only 6% of eligible
articipants were recruited to UK Biobank [21] . The data on medical
istory and medications may also be incomplete as it relies on partic-
pants’ self-reports, whereas in a clinical trial the investigators would
arefully check both a patient’s self-report and medical records. 
As SVD is a progressive condition, patients who have early features
f SVD on imaging are most likely to benefit from treatment intended to
revent the progression of the disease. Despite the drawbacks, we have
seful evidence that a trial of antiplatelet medication, antihypertensives
r statins would not struggle to recruit participants due to patients al-
eady taking the target medication. 
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